You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.


ontario regulation 172/01

made under the

Ontario drug benefit act

Made: May 16, 2001
Filed: May 17, 2001
Printed in The Ontario Gazette: June 2, 2001

Amending O. Reg. 201/96


Note: Since the end of 2000, Ontario Regulation 201/96 has been amended by Ontario Regulation 16/01.  Previous amendments are listed in the Table of Regulations published in The Ontario Gazette dated January 20, 2001.

1. (1) The definition of “Formulary” in subsection 1 (1) of Ontario Regulation 201/96 is revoked and the following substituted:

“Formulary” means the Ministry of Health publication titled “Drug Benefit Formulary/Comparative Drug Index” (No. 37) dated March 7, 2001, including the amendments to the publication dated June 7, 2001;

(2) Section 1 of the Regulation is amended by adding the following subsection:

(3) For the purposes of this Regulation, items 255 and 256 of Part III of the Formulary are deemed to read as follows:


5mg Tab












10mg Tab













Reason for

Use Code



Clinical criteria





For the initial trial for patients with mild to moderate Alzheimer’s disease (Mini-Mental State Exam [MMSE] 10-26), patients will be reimbursed for a period of up to three months after which continued treatment must be reassessed.




For continuation of therapy, further reimbursement will be made available to those patients whose disease has not progressed or deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.


2. (1) Subsection 1 (1) comes into force on June 7, 2001.

(2) Subsection 1 (2) comes into force on June 1, 2001.